RXRX — Recursion Pharmaceuticals, Inc.

Summary of RXRX Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Closed the quarter with $665 million in cash and equivalents, providing a runway through early 2028 without additional financing.
• Operating Expenses: Achieved a 30% year-over-year reduction in cash operating expenses, maintaining guidance of less than $390 million for 2026.
• Partnership Revenue: Generated over $500 million in inflows from partnerships, delivering 10 milestones to date.

2. Strategic Updates and Business Highlights

• AI-Driven Drug Development: Focus on leveraging AI to enhance drug discovery and development processes, with a commitment to financial discipline and capital allocation.
• Pipeline Progress: Five wholly-owned programs are advancing, with clear inflection points expected in the next 12 to 18 months.
  • REC-4881: First clinical proof of concept for an allosteric MEK1/2 inhibitor targeting familial adenomatous polyposis (FAP) showing significant polyp reduction.
  • REC-1245: Early clinical data for an RBM39 degrader indicates a well-tolerated profile with no dose-limiting toxicities.
  • REC-4539: First patient dosed in Phase I trial for an LSD1 inhibitor targeting solid tumors, with a focus on minimizing thrombocytopenia risks.
• Platform Development: Continued investment in an integrated AI-native product engine, enhancing capabilities in biology, chemistry, and clinical development.

3. Forward Guidance and Outlook

• Clinical Milestones: Anticipate multiple clinical readouts across wholly-owned programs over the next 12 to 18 months.
• Regulatory Engagement: Ongoing discussions with the FDA regarding registrational pathways for REC-4881, with a focus on defining clinically meaningful endpoints.
• Partnership Strategy: Expect further advancements in partnership programs, particularly with Sanofi and Roche, leading to potential opt-ins and clinical developments.

4. Bad News, Challenges, or Points of Concern

• Regulatory Uncertainties: The lack of regulatory precedent for REC-4881 poses challenges in defining the registrational pathway, particularly concerning patient population and clinical endpoints.
• Clinical Risks: While initial safety profiles are encouraging, ongoing dose escalation for REC-1245 and REC-4539 may reveal unforeseen toxicities.
• Market Competition: The competitive landscape in oncology and drug development remains intense, with the need for differentiation in a crowded market.

5. Notable Q&A Insights

• Target Engagement: Discussions highlighted the importance of achieving sufficient target engagement for efficacy, with ongoing monitoring of safety and tolerability for REC-1245.
• FDA Engagement: Emphasis on the proactive approach to regulatory discussions for REC-4881, including leveraging the rare disease framework to mitigate risks.
• Partnership Dynamics: Clarification on the balance between near-term milestones and long-term economics in partnerships, emphasizing a diversified risk model in the biotech space.

Overall, RXRX is demonstrating strong operational discipline and advancing its AI-driven drug development platform, while navigating regulatory challenges and competitive pressures in the industry.